Reach Us +1-504-608-2390
The Novel Reninangiotensin System, Inflammation And Hypertension | 7881
ISSN: 2155-9880

Journal of Clinical & Experimental Cardiology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

The novel reninangiotensin system, inflammation and hypertension

2nd International Conference on Clinical Research Cardiology, Ophthalmology & Dermatology

Jiu Chang Zhong, Haiyan Jin and Gavin Y. Oudit

ScientificTracks Abstracts: J Clinic Experiment Cardiol

DOI: 10.4172/2155-9880.S1.04

Hypertension is one of the most important risk factors for cardiovascular disease and stroke and has become an increasingly important contributor to the global health burden. However, the risk factors for hypertension are still largely unknown. Recently, chronic low grade low-grade inflammation has been identified as an integral part in the pathogenesis of vascular disease, including hypertension, either as a primary or secondary event. Reactive oxygen species (ROS) may directly alter vascular function or cause changes in vascular tone by several mechanisms including altered nitric oxide bioavailability and signaling and enhanced pro-inflammatory factors, which may contribute to vascular injury, remodeling and end-organ damage in hypertension. In the renin-angiotensin system (RAS), the activation of angiotensin II (Ang II) is an important mediator of oxidative stress and inflammation in hypertension. The newly-discovered angiotensin-converting enzyme 2 (ACE2), a carboxy-peptidase structurally related to ACE but resistant to ACE inhibitors. The key peptidase action of ACE2 is degradation of Ang II to Ang-(1-7), which exerts vasodilatory/ anti-proliferative/anti-inflammatory actions and functions effectively as a negative regulator of the RAS. In our recent research work, we have demonstrated that loss of ACE2 enhances the adverse pathological remodeling susceptibility to Ang II with elevated oxidative stress and inflammation in mice. Expression of proinflammatory cytokines, interleukin-1 b and chemokine (C-C motif) ligand 5, were increased in heart and kidney in ACE2 knockout mice in association with greater activation of extracellular-regulated kinase 1/2 and increase of protein kinase C levels. In contrast, human recombinant ACE2 prevents Ang II-induced oxidative stress, inflammation and pathological signaling in hypertension. Interventions such as ACE2 replenishment or augmentation of its actions have proven successful in reducing hypertension, and cardiac damage in a range of different models. ACE2 is abundantly expressed in the cardiovascular tissue and emerging evidence suggests a beneficial role for this enzyme against hypertension and cardiovascular diseases. Targeting the novel renin-angiotensin system by gene therapy or antibody treatment may provide a longer-term treatment for Patients with chronic inflammatory disease such as hypertension. This work was supported by National Natural Science Foundation of China (30973522 & 81170246), Shanghai Pujiang Talents Plan Project (11PJ1408300) and the Canadian Institute for Health Research Project (G.Y.O. 86602)